42 related articles for article (PubMed ID: 9393769)
1. The senescent mesothelial matrix accentuates colonization by ovarian cancer cells.
Thapa BV; Banerjee M; Glimm T; Saini DK; Bhat R
Cell Mol Life Sci; 2023 Dec; 81(1):2. PubMed ID: 38043093
[TBL] [Abstract][Full Text] [Related]
2. Microphysiological systems as models for immunologically 'cold' tumors.
Gaebler D; Hachey SJ; Hughes CCW
Front Cell Dev Biol; 2024; 12():1389012. PubMed ID: 38711620
[TBL] [Abstract][Full Text] [Related]
3. Integrins as attractive targets for cancer therapeutics.
Li M; Wang Y; Li M; Wu X; Setrerrahmane S; Xu H
Acta Pharm Sin B; 2021 Sep; 11(9):2726-2737. PubMed ID: 34589393
[TBL] [Abstract][Full Text] [Related]
4. Clinical correlation of opposing molecular signatures in head and neck squamous cell carcinoma.
Qadir F; Lalli A; Dar HH; Hwang S; Aldehlawi H; Ma H; Dai H; Waseem A; Teh MT
BMC Cancer; 2019 Aug; 19(1):830. PubMed ID: 31443700
[TBL] [Abstract][Full Text] [Related]
5. SATB1 plays an oncogenic role in esophageal cancer by up-regulation of FN1 and PDGFRB.
Song G; Liu K; Yang X; Mu B; Yang J; He L; Hu X; Li Q; Zhao Y; Cai X; Feng G
Oncotarget; 2017 Mar; 8(11):17771-17784. PubMed ID: 28147311
[TBL] [Abstract][Full Text] [Related]
6. Anti-vascular therapies in ovarian cancer: moving beyond anti-VEGF approaches.
Choi HJ; Armaiz Pena GN; Pradeep S; Cho MS; Coleman RL; Sood AK
Cancer Metastasis Rev; 2015 Mar; 34(1):19-40. PubMed ID: 25544368
[TBL] [Abstract][Full Text] [Related]
7. Integrin α5β1, the Fibronectin Receptor, as a Pertinent Therapeutic Target in Solid Tumors.
Schaffner F; Ray AM; Dontenwill M
Cancers (Basel); 2013 Jan; 5(1):27-47. PubMed ID: 24216697
[TBL] [Abstract][Full Text] [Related]
8. SOX2 targets fibronectin 1 to promote cell migration and invasion in ovarian cancer: new molecular leads for therapeutic intervention.
Lou X; Han X; Jin C; Tian W; Yu W; Ding D; Cheng L; Huang B; Jiang H; Lin B
OMICS; 2013 Oct; 17(10):510-8. PubMed ID: 23895273
[TBL] [Abstract][Full Text] [Related]
9. Loss of E-cadherin promotes ovarian cancer metastasis via alpha 5-integrin, which is a therapeutic target.
Sawada K; Mitra AK; Radjabi AR; Bhaskar V; Kistner EO; Tretiakova M; Jagadeeswaran S; Montag A; Becker A; Kenny HA; Peter ME; Ramakrishnan V; Yamada SD; Lengyel E
Cancer Res; 2008 Apr; 68(7):2329-39. PubMed ID: 18381440
[TBL] [Abstract][Full Text] [Related]
10. Role of integrin receptors for fibronectin, collagen and laminin in the regulation of ovarian carcinoma functions in response to a matrix microenvironment.
Ahmed N; Riley C; Rice G; Quinn M
Clin Exp Metastasis; 2005; 22(5):391-402. PubMed ID: 16283482
[TBL] [Abstract][Full Text] [Related]
11. Regulation of matrix metalloprotease activity in malignant mesothelioma cell lines by growth factors.
Liu Z; Klominek J
Thorax; 2003 Mar; 58(3):198-203. PubMed ID: 12612292
[TBL] [Abstract][Full Text] [Related]
12. Fibronectin activates matrix metalloproteinase-9 secretion via the MEK1-MAPK and the PI3K-Akt pathways in ovarian cancer cells.
Thant AA; Nawa A; Kikkawa F; Ichigotani Y; Zhang Y; Sein TT; Amin AR; Hamaguchi M
Clin Exp Metastasis; 2000; 18(5):423-8. PubMed ID: 11467775
[TBL] [Abstract][Full Text] [Related]
13. Integrin signaling in fibrosis and scleroderma.
Gardner HA
Curr Rheumatol Rep; 1999 Oct; 1(1):28-33. PubMed ID: 11123011
[TBL] [Abstract][Full Text] [Related]
14. Metastatic and non-metastatic colorectal cancer (CRC) cells induce host metalloproteinase production in vivo.
Mc Donnell S; Chaudhry V; Mansilla-Soto J; Zeng ZS; Shu WP; Guillem JG
Clin Exp Metastasis; 1999 Jun; 17(4):341-9. PubMed ID: 10545021
[TBL] [Abstract][Full Text] [Related]
15. Tumor-specific activation of mitogen-activated protein kinase in human colorectal and gastric carcinoma tissues.
Kuno Y; Kondo K; Iwata H; Senga T; Akiyama S; Ito K; Takagi H; Hamaguchi M
Jpn J Cancer Res; 1998 Sep; 89(9):903-9. PubMed ID: 9818025
[TBL] [Abstract][Full Text] [Related]
16. Fibronectin secretion from human peritoneal tissue induces Mr 92,000 type IV collagenase expression and invasion in ovarian cancer cell lines.
Shibata K; Kikkawa F; Nawa A; Suganuma N; Hamaguchi M
Cancer Res; 1997 Dec; 57(23):5416-20. PubMed ID: 9393769
[TBL] [Abstract][Full Text] [Related]
17. The different stimulatory effect of normal tissues on the secretion of matrix metalloproteinases and their inhibitors by human ovarian cancer cells.
Kikkawa F; Nawa A; Shibata K; Obata NH; Tamakoshi K; Suzuki S; Mizutani S
Anticancer Res; 1998; 18(6A):4323-8. PubMed ID: 9891486
[TBL] [Abstract][Full Text] [Related]
18. [Interactions of ovarian carcinoma cells and human peritoneal mesothelial cells involved in matrix metalloproteinases expressions of ovarian carcinoma cells].
Zhang JJ; Wang B
Zhonghua Fu Chan Ke Za Zhi; 2006 Mar; 41(3):194-7. PubMed ID: 16640888
[TBL] [Abstract][Full Text] [Related]
19. Beta1-integrins partly mediate binding of ovarian cancer cells to peritoneal mesothelium in vitro.
Strobel T; Cannistra SA
Gynecol Oncol; 1999 Jun; 73(3):362-7. PubMed ID: 10366461
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
